Stay updated on Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRecruitment status is updated to indicate that no more participants are being sought. A new revision (v3.6.0) has been added, while the earlier revision (v3.5.5) has been removed.SummaryDifference0.2%

- Check18 days agoChange DetectedThe record history now includes a new revision entry v3.5.5, and the previous revision v3.5.4 has been removed. This reflects an update to the page's versioning information within the study's history.SummaryDifference0.1%

- Check39 days agoChange DetectedThe record history now shows the latest revision (v3.5.4) as the current version, replacing the earlier v3.5.3 entry.SummaryDifference0.1%

- Check60 days agoChange DetectedThe page revision/version label was updated from v3.5.2 to v3.5.3, reflecting a site or interface version change rather than any update to the clinical trial record itself.SummaryDifference0.1%

- Check67 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0.SummaryDifference0.1%

- Check96 days agoChange DetectedRevision v3.5.0 was added to the record history and Revision v3.4.3 was removed.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page.